GRCE Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 344.05%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 396.18%. Given that Nanoviricides has higher upside potential than Grace Therapeutics, analysts believe Nanoviricides is more attractive than Grace Therapeutics.

Grace Therapeutics has a beta of 0.886, which suggesting that the stock is 11.36% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is lower than Nanoviricides's net income of -$2M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 344.05%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 413.88%. Given that Oragenics has higher upside potential than Grace Therapeutics, analysts believe Oragenics is more attractive than Grace Therapeutics.

Grace Therapeutics has a beta of 0.886, which suggesting that the stock is 11.36% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is lower than Oragenics's net income of -$3.3M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

SpringWorks Therapeutics has a net margin of -- compared to Grace Therapeutics's net margin of -169.47%. Grace Therapeutics's return on equity of -- beat SpringWorks Therapeutics's return on equity of -49.69%.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 344.05%. On the other hand SpringWorks Therapeutics has an analysts' consensus of $47.00 which suggests that it could grow by 2%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

Grace Therapeutics has a beta of 0.886, which suggesting that the stock is 11.36% less volatile than S&P 500. In comparison SpringWorks Therapeutics has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.596%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SpringWorks Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. SpringWorks Therapeutics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than SpringWorks Therapeutics quarterly revenues of $49.1M. Grace Therapeutics's net income of -$4.2M is higher than SpringWorks Therapeutics's net income of -$83.2M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while SpringWorks Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 15.61x for SpringWorks Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Grace Therapeutics's net margin of --. Grace Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Grace Therapeutics has a consensus price target of $11.86, signalling upside risk potential of 344.05%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1193.66%. Given that Theriva Biologics has higher upside potential than Grace Therapeutics, analysts believe Theriva Biologics is more attractive than Grace Therapeutics.

Grace Therapeutics has a beta of 0.886, which suggesting that the stock is 11.36% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Grace Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grace Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Grace Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Grace Therapeutics's net income of -$4.2M is higher than Theriva Biologics's net income of -$4.4M. Notably, Grace Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grace Therapeutics is -- versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.